Sign in with Google. Opens in new tab
bullish
Genor Biopharma IPO: Strong Clinical Pipeline with Some Potential Blockbusters
421 Views17 Sep 2020 08:25
JHBP (CY) Holdings Ltd also known as Genor Biopharma has filed for an IPO on the Hong Kong Stock Exchange to raise about HK$2.48bn (US$320m). The...
SUMMARY
(Sign Up to Access)Full Insight
(Paid Plans Only, 8-minute read)
Related Insights
More »Loading
Trending Collections
More »Trending Insights
More »- Santos Ltd (STO AU): FIRB Approval For XRG's Tilt Will Be No Pushover
- Gold Miners ETF (GDX US): BIG Impact of Benchmark Change
- SET50 Index Rebalance: Four Changes in Two Weeks; DELTA Capping Too
- Nakano Refrigerators (6411 JP): Marunouchi Capital’s JPY7,900 Tender Offer
- Shin Kong (2888 TT)/Taishin (2887 TT) - Short Timer, FX Risk, Index Flows - Time To Buy Vs Peers
Top Unpaywalled Insights
More »- Overview #27 – The Big Beautiful Tragi-Comedy Continues
- HK Connect SOUTHBOUND Flows (To 13 June 2025); Volumes Up, TECH Down, HEALTHCARE Bought Big
- [IO Technicals 2025/24] Downward Momentum Lingers
- China A-Share Consumer Staples: An Analysis of the Opportunities Ahead
- Bearishness Persist in Soybeans Despite Rebound Hopes
Discussions
(Paid Plans Only)
Price Chart(Sign Up to Access)
- M3 Inc: Intelligent Adaption to Covid-19 Should Sustain Medtech Earnings Growth Even Post-Pandemic24 Sep 2020
- GoodRx IPO: A Healthy Prescription for Strong Topline Growth and Profits21 Sep 2020
- ZTO Express Secondary: Overvalued and More Expensive than Global Delivery Giants18 Sep 2020
- Genor Biopharma IPO: Strong Clinical Pipeline with Some Potential Blockbusters17 Sep 2020
- ZTO Secondary: Entire Industry Expanding Capacity While Facing Pricing Pressure Is Not a Good Thing16 Sep 2020
- Hygeia Healthcare IPO (Part II): Healthy Valuation17 Jun 2020
- Venus Medtech IPO: First Mover Advantage in Chinese TAVR Market to Support Growth12 Aug 2019
x